|
Drug
|
No of isolates
|
LPA + MGIT R
|
LPA + MGIT S
|
LPA R MGIT S
|
LPA S MGIT R
|
Sensitivity (%)
|
Specificity (%)
|
PPV (%)
|
NPV (%)
|
Agreement (%)
|
K-Value
|
|---|
|
aRIF
|
97
|
14
|
73
|
10
|
0
|
100 (76.8–100)
|
87.9(78.9–94.1)
|
58.3 (43.9–71.5)
|
100
|
89.7
|
0.68
|
|
aINH
|
97
|
43
|
51
|
3
|
0
|
100 (91.8–100)
|
94.4 (84.6–98.8)
|
93.5 (82.7–97.7)
|
100
|
96.9
|
0.93
|
|
aOFL
|
90
|
9
|
74
|
7
|
0
|
100 (66.3–100)
|
91.4 (83.0–96.4)
|
56.2(38.8–72.3)
|
100
|
92.2
|
0.68
|
|
aKAN
|
90
|
3
|
85
|
2
|
0
|
100 (29.2–100)
|
97.7(91.9–99.7)
|
60.0(27.60–85.5)
|
100
|
97.8
|
0.74
|
|
aEMB
|
90
|
15
|
58
|
7
|
10
|
60 (38.7–78.9)
|
89.2(79.06–95.56)
|
68.2(49.8–82.2)
|
85.3(78.1–90.4)
|
81.1
|
0.54
|
-
a
RIF Rifampicin, INH Isoniazid, OFX Ofloxacin, KAN Kanamycin, EMB Ethambutol, S susceptible, R resistant, LPA Line Probe Assay, PPV positive predictive value, NPV negative predictive value
